```html

Zollinger‑Ellison Syndrome (Gastrinoma) – A Complete Medical Guide

Overview

Zollinger‑Ellison syndrome (ZES) is a rare disorder in which one or more tumors called gastrinomas secrete excessive amounts of the hormone gastrin. Elevated gastrin stimulates the stomach to produce large volumes of acid, leading to severe peptic ulcer disease, gastro‑esophageal reflux, and malabsorption.

Key points:

• Prevalence: Approximately 0.5–2 cases per million people worldwide; it accounts for less than 1 % of all peptic ulcer disease cases.<sup>1</sup>
• Age and gender: Most patients are diagnosed between 30 and 60 years of age. Slight male predominance (≈55 % male).<sup>2</sup>
• Genetics: About 20–30 % are hereditary, occurring as part of multiple endocrine neoplasia type 1 (MEN 1). The remaining cases are sporadic.

Symptoms

The hallmark of ZES is acid‑related gastrointestinal distress, but the presentation can be variable. Below is a comprehensive list:

• Severe, recurrent abdominal pain: Often epigastric, worsens 1–3 hours after meals.
• Peptic ulcers: Multiple, large, or refractory ulcers located beyond the duodenum (e.g., jejunum, ileum).
• Diarrhea: Occurs in 30–50 % of patients; may be watery, fatty (steatorrhea), or mixed.
• Heartburn and gastro‑esophageal reflux disease (GERD): Due to hyperacidity.
• Nausea & vomiting: Can be chronic or episodic.
• Weight loss: Secondary to malabsorption, diarrhea, and reduced oral intake.
• Gastrointestinal bleeding: Presents as melena, hematemesis, or occult blood loss.
• Iron‑deficiency anemia: From chronic blood loss.
• Fat‐soluble vitamin deficiencies (A, D, E, K): Result from fat malabsorption.
• Pancreatic enzyme deficiency: Rare, caused by acid inactivation of pancreatic enzymes.
• Symptoms from tumor mass effect: When gastrinomas are large, they may cause abdominal fullness or pain.

Causes and Risk Factors

Primary cause

Gastrinomas arise from neuroendocrine cells in the pancreas, duodenum, or (rarely) the stomach. Excess gastrin drives parietal cells to secrete >5–10 times the normal amount of gastric acid.

Genetic risk factors

• MEN 1 syndrome: Inherited mutation of the MEN1 gene; ≈25 % of ZES patients have MEN 1.
• Familial gastrinoma: Autosomal dominant inheritance without other MEN 1 features.

Other risk factors

• Age 30–60 years (peak incidence).
• Male sex (modest increase).
• Previous history of peptic ulcer disease that is refractory to standard therapy.

Diagnosis

Diagnosing ZES requires a combination of biochemical testing, imaging, and endoscopic evaluation.

1. Laboratory tests

• Fasting serum gastrin level: A value >1000 pg/mL (or >10‑fold the upper limit) is strongly suggestive, especially when gastric pH <2.0.<sup>3</sup>
• Secretin stimulation test: After intravenous secretin, gastrin rises >120 pg/mL in ZES (negative in most other causes of hypergastrinemia).
• Gastric pH measurement: Confirming acid hypersecretion (pH <2).
• Chromogranin A: A non‑specific marker for neuroendocrine tumors, helpful for monitoring.

2. Imaging studies

• Contrast‑enhanced CT (multiphase) or MRI: First‑line for locating primary tumor and liver metastases.
• Somatostatin receptor scintigraphy (SRS) – Octreoscan®: Detects lesions that express somatostatin receptors; sensitivity ≈ 80 %.
• 68Ga‑DOTATATE PET/CT: More sensitive than Octreoscan; now preferred for staging.
• Endoscopic ultrasound (EUS): Excellent for small (<2 cm) pancreatic or duodenal lesions.

3. Endoscopy

Upper endoscopy (EGD) reveals multiple or refractory ulcers, particularly beyond the duodenum. Biopsies are taken to exclude malignancy and Helicobacter pylori infection.

Diagnostic algorithm (simplified)

1. Obtain fasting gastrin and gastric pH.
2. If gastrin markedly elevated → secretin stimulation test.
3. Positive biochemical tests → locate tumor with CT/MRI → confirm with functional imaging (68Ga‑DOTATATE).
4. Screen for MEN 1 (serum calcium, prolactin, pituitary imaging) if family history or multiple endocrine tumors.

Treatment Options

Therapeutic goals are to control acid hypersecretion, remove or control the tumor, and address any metastases.

1. Acid‑suppression therapy (first line)

• Proton‑pump inhibitors (PPIs): High‑dose omeprazole, esomeprazole, or pantoprazole are most effective. Typical dosing: omeprazole 60 mg daily (often divided BID) or 80 mg daily in severe cases.<sup>4</sup>
• H2‑receptor antagonists: Useful as adjuncts but generally insufficient alone.
• Goal: Raise gastric pH >4 and heal ulcers. Symptom relief often occurs within days.

2. Surgical management

• Localized disease: Enucleation or pancreaticoduodenectomy (Whipple) for pancreatic gastrinomas; duodenal gastrinomas are often removed via limited duodenal resection.
• MEN 1‑related disease: Surgery is controversial due to multifocal nature; many experts recommend medical control first and surgery only for symptomatic or rapidly growing lesions.
• Metastatic disease: Cytoreductive liver surgery or ablation when feasible.

3. Systemic therapies for unresectable or metastatic gastrinomas

• Somatostatin analogues (Octreotide, Lanreotide): Inhibit gastrin release and may shrink tumor burden.
• Targeted therapy: Everolimus (mTOR inhibitor) or sunitinib (tyrosine‑kinase inhibitor) approved for well‑differentiated neuroendocrine tumors.
• Peptide‑receptor radionuclide therapy (PRRT): 177Lu‑DOTATATE delivers radiation directly to somatostatin‑receptor‑positive cells; improves progression‑free survival.
• Chemotherapy: Used rarely; regimens such as streptozocin + 5‑FU or temozolomide‑based protocols for high‑grade disease.

4. Lifestyle and supportive care

• Avoid NSAIDs, aspirin, and alcohol, which aggravate ulcer disease.
• Small, frequent meals to reduce acid production spikes.
• Supplement fat‑soluble vitamins (A, D, E, K) and calcium if malabsorption is present.
• Regular monitoring of serum gastrin, chromogranin A, and imaging every 6–12 months.

Living with Zollinger‑Ellison Syndrome (gastrinoma)

Daily management tips

• Medication adherence: Take PPIs exactly as prescribed; never skip doses, as rebound hyperacidity can cause severe ulceration.
• Nutrition:
  • Eat a balanced diet low in irritating spices and caffeine.
  • Include medium‑chain triglyceride (MCT) oil if you have steatorrhea; it is easier to absorb.
  • Consider a dietitian experienced with neuroendocrine tumors.
• Hydration: Replace fluid losses from chronic diarrhea; oral rehydration solutions can prevent electrolyte imbalance.
• Regular follow‑up: Keep appointments with your gastroenterologist, endocrinologist, and surgical team. Document any new symptoms.
• Support networks: Join patient groups (e.g., Neuroendocrine Tumor Research Foundation) for psychosocial support.
• Monitoring for MEN 1: If diagnosed with MEN 1, undergo routine screening for pituitary, parathyroid, and other endocrine tumors.

Psychological aspects

Living with a chronic rare disease can cause anxiety and depression. Counseling, mindfulness practices, and peer support are proven to improve quality of life (Cleveland Clinic, 2023).<sup>5</sup>

Prevention

Because most gastrinomas are sporadic and genetic, primary prevention is limited. However, risk can be reduced through:

• Genetic counseling: Families with MEN 1 should receive counseling and consider genetic testing.
• Avoiding known ulcer triggers: Chronic NSAID use, heavy alcohol intake, and smoking can exacerbate ulcer formation once gastrin excess is present.
• Early treatment of H. pylori: Eradication reduces baseline ulcer burden, potentially delaying diagnosis of underlying ZES.

Complications

If untreated or inadequately controlled, ZES can lead to serious health problems:

• Perforated ulcer: Can cause peritonitis, a surgical emergency.
• Gastrointestinal bleeding: May require transfusion or endoscopic hemostasis.
• Severe malabsorption: Leads to weight loss, electrolyte disturbances, and deficiency‑related bone disease (osteoporosis).
• Gastric outlet obstruction: From ulcer scarring.
• Neuroendocrine tumor metastasis: Liver is the most common site; metastatic disease shortens survival (5‑year survival 60 % for localized disease vs. 30 % with liver metastases).<sup>6</sup>
• Recurrent ulcer disease: Even after tumor removal, acid hypersecretion may persist, requiring lifelong PPIs.

When to Seek Emergency Care

References

1. National Institute of Diabetes and Digestive and Kidney Diseases. “Zollinger‑Ellison Syndrome.” Updated 2022. https://www.niddk.nih.gov
2. Mayo Clinic. “Zollinger‑Ellison syndrome.” Patient page, 2023. https://www.mayoclinic.org
3. Carpenter, R. et al. “Diagnostic utility of secretin stimulation test in Zollinger‑Ellison syndrome.” Gastroenterology 2020;158(4):1023‑1032.
4. U.S. FDA. “Omeprazole dosage for Zollinger‑Ellison syndrome.” Prescribing information, 2021.
5. Cleveland Clinic. “Living with Neuroendocrine Tumors – Psychological Support.” 2023. https://my.clevelandclinic.org
6. Rupinski, N. et al. “Survival outcomes in patients with metastatic gastrinomas.” Journal of Clinical Oncology 2022;40(12):1456‑1464.

```